FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics, namely to a pharmaceutical composition possessing a property of vitamin D receptor (VDR) activation. The oral pharmaceutical composition contains paricalcitol as an active component, and a polar carrier representing sodium caseinate or fatty acid mono- and/or diglycerides; the paricalcitol content is from 0.0005 to 0.012 wt %.
EFFECT: composition possesses high stability and preserved high clinical effectiveness that is ensured by using the polar carrier representing fatty acid mono- and/or diglycerides or sodium caseinate.
5 cl, 3 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SUPERCRITICAL LIQUID EXTRACT CONTAINING CARDIAC GLYCOSIDE | 2006 |
|
RU2398591C2 |
| PHARMACEUTICAL COMPOSITIONS | 2011 |
|
RU2639482C2 |
| PHARMACEUTICAL COMPOSITION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME | 2018 |
|
RU2779262C2 |
| OIL-IN-WATER EMULSION AND USE THEREOF IN ENDOWING FUNCTIONALITY | 2006 |
|
RU2426440C2 |
| PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN | 2008 |
|
RU2484816C2 |
| BENZIMIDAZOLYLPYRIDYL ESTER COMPOUNDS | 2007 |
|
RU2452469C2 |
| RACECADOTRIL LIPID COMPOSITIONS | 2014 |
|
RU2662069C2 |
| USE OF SORBITAN DERIVATIVE TO PREVENT FAT ABSORPTION | 2005 |
|
RU2386365C2 |
| THREE-PHASE PHARMACEUTICAL FORM WITH CONSTANT AND CONTROLLED RELEASE OF AMORPHOUS ACTIVE INGREDIENT FOR SINGLE DAILY ADMINISTRATION | 1996 |
|
RU2161956C2 |
| LIPID COMPOSITIONS OF RACECADOTRIL | 2013 |
|
RU2632441C2 |
